MA40761A - Utilisation de panels de gènes mutants du fgfr dans l'identification de patients atteints de cancer qui seront sensibles à un traitement avec un inhibiteur du fgfr - Google Patents

Utilisation de panels de gènes mutants du fgfr dans l'identification de patients atteints de cancer qui seront sensibles à un traitement avec un inhibiteur du fgfr

Info

Publication number
MA40761A
MA40761A MA040761A MA40761A MA40761A MA 40761 A MA40761 A MA 40761A MA 040761 A MA040761 A MA 040761A MA 40761 A MA40761 A MA 40761A MA 40761 A MA40761 A MA 40761A
Authority
MA
Morocco
Prior art keywords
fgfr
cancer
sensitive
treatment
mutant gene
Prior art date
Application number
MA040761A
Other languages
English (en)
Other versions
MA40761B1 (fr
Inventor
Jayaprakash Karkera
Suso Jesus Platero
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA40761A publication Critical patent/MA40761A/fr
Publication of MA40761B1 publication Critical patent/MA40761B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
MA40761A 2014-09-26 2015-09-18 Utilisation de panels de gènes mutants du fgfr dans l'identification de patients atteints de cancer qui seront sensibles à un traitement avec un inhibiteur du fgfr MA40761B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462056159P 2014-09-26 2014-09-26
PCT/US2015/050996 WO2016048833A2 (fr) 2014-09-26 2015-09-18 Utilisation de panels de gènes mutants du fgfr dans l'identification de patients atteints de cancer qui seront sensibles à un traitement avec un inhibiteur du fgfr

Publications (2)

Publication Number Publication Date
MA40761A true MA40761A (fr) 2017-08-01
MA40761B1 MA40761B1 (fr) 2022-04-29

Family

ID=54337343

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40761A MA40761B1 (fr) 2014-09-26 2015-09-18 Utilisation de panels de gènes mutants du fgfr dans l'identification de patients atteints de cancer qui seront sensibles à un traitement avec un inhibiteur du fgfr

Country Status (37)

Country Link
US (2) US20160090633A1 (fr)
EP (2) EP3198033B1 (fr)
JP (3) JP6766037B2 (fr)
KR (2) KR102470456B1 (fr)
CN (2) CN107002141B (fr)
AR (1) AR102345A1 (fr)
AU (2) AU2015321626B2 (fr)
BR (1) BR112017006088A2 (fr)
CA (1) CA2962075A1 (fr)
CO (1) CO2017003528A2 (fr)
CR (1) CR20170104A (fr)
DK (1) DK3198033T3 (fr)
EA (1) EA037920B1 (fr)
EC (1) ECSP17025787A (fr)
ES (1) ES2912567T3 (fr)
GT (1) GT201700059A (fr)
HR (1) HRP20220496T1 (fr)
HU (1) HUE058219T2 (fr)
IL (2) IL251264B (fr)
JO (1) JO3681B1 (fr)
LT (1) LT3198033T (fr)
MA (1) MA40761B1 (fr)
MX (2) MX2017003954A (fr)
MY (1) MY194567A (fr)
NI (1) NI201700035A (fr)
PH (1) PH12017500556A1 (fr)
PL (1) PL3198033T3 (fr)
PT (1) PT3198033T (fr)
RS (1) RS63178B1 (fr)
SG (1) SG11201702381QA (fr)
SI (1) SI3198033T1 (fr)
SV (1) SV2017005415A (fr)
TW (1) TWI706136B (fr)
UA (1) UA122564C2 (fr)
UY (1) UY36325A (fr)
WO (1) WO2016048833A2 (fr)
ZA (1) ZA201702899B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2902489B9 (fr) 2012-09-27 2018-02-07 Chugai Seiyaku Kabushiki Kaisha Gène de fusion fgfr3 et médicament pharmaceutique ciblant celui-ci
WO2015111716A1 (fr) 2014-01-24 2015-07-30 公益財団法人がん研究会 Nouvelle élément de fusion et son procédé de détection
SI3122358T1 (sl) 2014-03-26 2021-04-30 Astex Therapeutics Ltd. Kombinacije FGFR- in CMET-inhibitorjev za zdravljenje raka
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
KR20220110859A (ko) * 2016-03-04 2022-08-09 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
JOP20190280A1 (ar) 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
JP2022501355A (ja) * 2018-09-21 2022-01-06 ヤンセン ファーマシューティカ エヌ．ベー． 胆管癌の処置
SG11202109902SA (en) 2019-03-29 2021-10-28 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
CA3130773A1 (fr) 2019-03-29 2020-10-08 Peter Marie Z. De Porre Inhibiteurs de la tyrosine kinase fgfr pour le traitement du carcinome urothelial
AU2020282816A1 (en) * 2019-05-31 2022-01-06 Qed Therapeutics, Inc. Methods of treating urinary system cancers
CN110241183B (zh) * 2019-06-13 2022-10-28 南京世和基因生物技术股份有限公司 一种fgfr融合基因的检测方法、试剂盒以及探针库
US20220307078A1 (en) * 2019-09-09 2022-09-29 Zepto Life Technology, LLC Systems and methods for detecting genetic variation in nucleic acids
MX2022003686A (es) 2019-09-26 2022-04-25 Janssen Pharmaceutica Nv Uso de inhibidores de fgfr en canceres geneticamente alterados para mejorar la respuesta de los pacientes a los inhibidores de puntos de control inmunitarios en entornos de tratamiento secuencial.
AU2021220285A1 (en) 2020-02-12 2022-10-06 Janssen Pharmaceutica Nv FGFR tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
TW202140012A (zh) 2020-02-12 2021-11-01 比利時商健生藥品公司 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑
AU2021254793A1 (en) * 2020-04-15 2022-11-17 Alkermes Pharma Ireland Limited Immunostimulatory agents in combination with angiogenesis inhibitors
CN111440790A (zh) * 2020-05-08 2020-07-24 公安部物证鉴定中心 唾液斑迹dna和rna同时提取的方法
MX2023002980A (es) 2020-09-14 2023-06-06 Janssen Pharmaceutica Nv Terapias de combinación de inhibidores del fgfr.
CN112143815B (zh) * 2020-11-25 2021-02-26 江苏申基生物科技有限公司 一种用于检测人fgfr2基因融合突变的核酸组合物、试剂盒及检测方法
WO2022243467A1 (fr) 2021-05-19 2022-11-24 Janssen Pharmaceutica Nv Inhibiteurs de tyrosine kinase fgfr destinés au traitement des tumeurs solides avancées
WO2023064830A1 (fr) 2021-10-12 2023-04-20 Taris Biomedical Llc Formulations d'erdafitinib et systèmes d'administration intravésicale
WO2023159216A1 (fr) 2022-02-18 2023-08-24 Taris Biomedical Llc Formulations d'erdafitinib et systèmes osmotiques pour administration intravésicale

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035803A2 (fr) 2002-10-01 2004-04-29 Epigenomics Ag Procede et acides nucleiques permettant d'ameliorer le traitement de troubles de la proliferation de celllules mammaires
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP1659175A1 (fr) * 2004-11-18 2006-05-24 Institut Curie Altérations des kératoses séborrhéiques et applications dérivées
CN101218228A (zh) 2005-05-23 2008-07-09 诺瓦提斯公司 4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮乳酸盐的结晶和其它形式
EP1964837A4 (fr) * 2005-11-22 2010-12-22 Eisai R&D Man Co Ltd Agent antitumeur pour myelomes multiples
JP2009523410A (ja) * 2005-12-08 2009-06-25 ノバルティス アクチエンゲゼルシャフト 遺伝子転写に対するｆｇｆｒ３の阻害剤の効果
EP1918376A1 (fr) * 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 favorise la résistance des cellules cancéreuses en réponse aux agents chimiothérapeutiques
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
US8071338B2 (en) 2007-08-08 2011-12-06 Roche Molecular Systems, Inc. Suppression of amplification using an oligonucleotide and a polymerase significantly lacking 5′-3′ nuclease activity
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) * 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
CN102293770A (zh) * 2011-05-25 2011-12-28 温州医学院 新型成纤维细胞生长因子受体酪氨酸激酶抑制剂
CN102319224B (zh) * 2011-07-27 2013-03-20 赛乐医药科技(上海)有限公司 复方甲氧那明的速释－缓释渗透泵制剂
WO2013026027A1 (fr) 2011-08-18 2013-02-21 Nestec S.A. Compositions et procédés pour la détection de variants alléliques
WO2013089882A2 (fr) * 2011-09-27 2013-06-20 The Regents Of The University Of Michigan Fusions de gènes récurrentes dans le cancer du sein
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
WO2013088191A1 (fr) * 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagoniste du récepteur 3 du facteur de croissance des fibroblastes (fgfr3) à utiliser dans le traitement ou la prévention de troubles squelettiques liés à une activation anormale du fgfr3
AR090161A1 (es) * 2012-02-28 2014-10-22 Astellas Pharma Inc Derivados heterociclicos nitrogenados con accion sobre el cancer de vejiga
US9254288B2 (en) * 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
GB201209609D0 (en) * 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
JPWO2014007369A1 (ja) * 2012-07-05 2016-06-02 国立研究開発法人国立がん研究センター Ｆｇｆｒ２融合遺伝子
EP4276200A3 (fr) * 2012-07-24 2024-02-14 The Trustees of Columbia University in the City of New York Fgfr-tacc protéines de fusion et leurs procédés associés
KR20150037876A (ko) * 2012-07-27 2015-04-08 제넨테크, 인크. Fgfr3 관련 상태의 치료 방법
EP2902489B9 (fr) * 2012-09-27 2018-02-07 Chugai Seiyaku Kabushiki Kaisha Gène de fusion fgfr3 et médicament pharmaceutique ciblant celui-ci
ES2949394T3 (es) * 2012-11-05 2023-09-28 Found Medicine Inc Moléculas de fusión novedosas y usos de las mismas
CA3150658A1 (en) * 2013-01-18 2014-07-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma

Also Published As

Publication number Publication date
ES2912567T3 (es) 2022-05-26
PL3198033T3 (pl) 2022-08-29
MX2022006536A (es) 2022-07-11
AU2015321626A1 (en) 2017-04-06
RS63178B1 (sr) 2022-06-30
IL251264B (en) 2022-04-01
CR20170104A (es) 2017-05-31
MA40761B1 (fr) 2022-04-29
AR102345A1 (es) 2017-02-22
IL291633A (en) 2022-05-01
HRP20220496T1 (hr) 2022-05-27
US20190078166A1 (en) 2019-03-14
SV2017005415A (es) 2017-07-03
ZA201702899B (en) 2019-06-26
MY194567A (en) 2022-12-02
HUE058219T2 (hu) 2022-07-28
CN113957146A (zh) 2022-01-21
CA2962075A1 (fr) 2016-03-31
JO3681B1 (ar) 2020-08-27
IL251264A0 (en) 2017-05-29
CN107002141A (zh) 2017-08-01
JP2020124192A (ja) 2020-08-20
EA201790716A1 (ru) 2017-10-31
EP3198033B1 (fr) 2022-02-16
JP2017529090A (ja) 2017-10-05
JP6766037B2 (ja) 2020-10-07
LT3198033T (lt) 2022-05-10
WO2016048833A2 (fr) 2016-03-31
BR112017006088A2 (pt) 2017-12-19
SG11201702381QA (en) 2017-04-27
UA122564C2 (uk) 2020-12-10
MX2017003954A (es) 2017-12-14
ECSP17025787A (es) 2018-07-31
EP3198033A2 (fr) 2017-08-02
NI201700035A (es) 2017-06-22
KR20170062495A (ko) 2017-06-07
CN107002141B (zh) 2021-11-02
KR102470456B1 (ko) 2022-11-23
AU2015321626B2 (en) 2021-12-16
PH12017500556A1 (en) 2017-08-30
KR20220162823A (ko) 2022-12-08
JP7051920B2 (ja) 2022-04-11
CO2017003528A2 (es) 2017-07-11
WO2016048833A3 (fr) 2016-05-19
PT3198033T (pt) 2022-05-25
EA037920B1 (ru) 2021-06-07
AU2021277633A1 (en) 2021-12-23
US20160090633A1 (en) 2016-03-31
TWI706136B (zh) 2020-10-01
GT201700059A (es) 2019-08-21
JP2022109910A (ja) 2022-07-28
UY36325A (es) 2016-04-01
SI3198033T1 (sl) 2022-06-30
EP4063516A1 (fr) 2022-09-28
TW201619609A (zh) 2016-06-01
DK3198033T3 (da) 2022-04-11

Similar Documents

Publication Publication Date Title
MA40761A (fr) Utilisation de panels de gènes mutants du fgfr dans l'identification de patients atteints de cancer qui seront sensibles à un traitement avec un inhibiteur du fgfr
IL261882A (en) A system for variant-phenotype genetic analysis and methods for use
MA47594A (fr) Utilisation de biomarqueurs dans l'identification de patients atteints d'un cancer sensibles à un traitement avec un inhibiteur de prmt5
EP3464638A4 (fr) Utilisation de biomarqueurs pour déterminer la sensibilité au traitement d'une maladie
ZA201808186B (en) Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death
HK1250520A1 (zh) 比對和變體測序分析管線
EP3186397C0 (fr) Utilisation de biomarqueurs de cellules circulant dans le sang pour la détection et le diagnostic de maladies, et leurs procédés d'isolement
MA39960A (fr) Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer
DK3149019T3 (da) Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme
IL253308A0 (en) Sex-determining genes and their use in breeding
HK1247287A1 (zh) 檢測和定量il-13的方法和在診斷和治療th2相關疾病中的用途
MA46783A (fr) Polythérapie de type thérapie cellulaire t et inhibiteur de btk
DK3233129T3 (da) Nukleinsyrekonstrukter og genterapivektorer til anvendelse i behandlingen af wilsons sygdom og andre lidelser
FR3059009B1 (fr) Microcompartiment cellulaire et procedes de preparation
FR3026745B1 (fr) Methode d'analyse et interpretation automatisee d'un antibiogramme
MA43106A (fr) Traitement de l'oligo-ovulation associée à la stéatose hepatique
NZ766149A (en) Detection of deletions and copy number variations in DNA sequences
FR3007287B1 (fr) Composition comprenant l'association d'un polymere acrylique et d'une silicone aminee
MA42913A (fr) Pyridazinones et leur utilisation dans le traitement du cancer
GB201615837D0 (en) Methods and apparatus for identifying one or more genetic variants associated with disease in an individual or group of related individuals
FR3021520B1 (fr) Canule d'ablation et kit avec insert
MA42914A (fr) Composés tricycliques et leur utilisation dans le traitement du cancer
FR3020471B1 (fr) Procede de traitement de surface d'une piece transparente et piece ainsi traitee
FR3015731B1 (fr) Procede d'estimation du nombre de personnes et ou d'obets dans un espace
MA40870A (fr) Utilisation d'alliage d'alumine-chrome dans un traitement thermique